Sanofi paid a more than 300% premium on its acquisition of Vigil Neuroscience, suggesting a fierce battle to seal the deal.

AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications ...

Fintel reports that on June 17, 2025, Wolfe Research initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a ...

SynaptixBio announces milestone with selection of candidate drug to treat rare disease H-ABC: Our Bureau, Bengaluru Friday, June 20, 2025, 12:30 Hrs [IST] Oxford-based SynaptixBio ...

Discover six kidney disease companies actively working on innovative treatments that could make a difference to patients' lives.

Down Syndrome, caused by an extra copy of chromosome 21, is one of the most common chromosomal disorders, marked by ...

Oligonucleotide Therapies- Overcoming The Challenges Of Delivery led by Nick Lench, Executive Director, NATA, Martin Kerr, Head of Business Development & Partnerships, Nucleic Acid Therapy ...

Owing to the growing need for new drug classes, demand for oligonucleotide APIs is projected to rise at a high CAGR of 5.60% from 2024 to 2034. As such, the global oligonucleotide API market is ...

Panelists discuss how recent advancements in muscular dystrophy treatment have evolved toward truly disease-modifying ...

AOC delivers oligonucleotides synthesized from such RNA to cells with mutated genes. Existing RNA therapies have the same mechanism of action, but they have limitations in distinguishing target cells.

Researchers from Waters and Biospring studied the contribution of nucleotide type and modifications on the retention and resolution of 22–24 nt long oligonucleotides in different chromatographic ...